.@myESMO Presidential Symposium Spotlight: A chemo-free option after osimertinib? In the phase 3 SAFFRON trial, osimertinib + savolitinib improved PFS (HR, 0.55) and OS (HR, 0.68) vs platinum/pemetrexed in EGFR+ NSCLC with MET overexpression/amplification.

Full #ESMO26 data: https://www.onclive.com/view/saffron-data-reveal-new-global-soc-in-egfr-nsclc-with-met-overexpression-and-or-amplification-after-osimertinib

#medtwitter #oncology #lcsm